Factors Driving Persistence to First-Line Advanced Therapies in Inflammatory Bowel Disease - A Real-World Study

被引：0
|
作者：
Santacroce, G. [1 ,2 ]
Lenti, M., V [1 ,2 ]
Lepore, F. [1 ,2 ]
Morda, F. [1 ,2 ]
Lo Bello, A. [1 ,2 ]
Aronico, N. [2 ]
Mengoli, C. [2 ]
Delliponti, M. [3 ]
Di Sabatino, A. [1 ,2 ]
机构：
[1] Univ Pavia, Dept Internal Med & Med Therapeut, Pavia, Italy
[2] San Matteo Hosp Fdn, Dept Internal Med 1, Pavia, Italy
[3] San Matteo Hosp Fdn, SSD Biostat & Clin Trial, Pavia, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1351
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1177
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-Line Therapies in Inflammatory Bowel Disease
    Girardin, Marc
    Manz, Michael
    Manser, Christine
    Biedermann, Luc
    Wanner, Roger
    Frei, Pascal
    Safroneeva, Ekaterina
    Mottet, Christian
    Rogler, Gerhard
    Schoepfer, Alain M.
    DIGESTION, 2012, 86 : 6 - 10
  • [2] Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis
    Dalal, Rahul S.
    Clarke, Lindsay M.
    Carlin, Alex
    Cabral, Heidy
    Allegretti, Jessica R.
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [3] Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma
    Haack, Maximilian
    Neuberger, Stephanie
    Boerner, Jan Hendrik
    Ziewers, Stefanie
    Duwe, Gregor
    Dotzauer, Robert
    Haferkamp, Axel
    Mager, Rene
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [4] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Brian Bressler
    Jennifer Jones
    Tracy S. H. In
    Tommy Lan
    Cristian Iconaru
    John K. Marshall
    Advances in Therapy, 2023, 40 : 4421 - 4439
  • [5] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Bressler, Brian
    Jones, Jennifer
    In, Tracy S. H.
    Lan, Tommy
    Iconaru, Cristian
    Marshall, John K.
    ADVANCES IN THERAPY, 2023, 40 (10) : 4421 - 4439
  • [6] Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study
    Fernandez-Cano, Maria Carmen
    Fernandez-Cano, Antonio Jesus
    Martin-Rodriguez, Maria Mar
    Sanchez-Capilla, Antonio Damian
    Cabello-Tapia, Maria Jose
    Redondo-Cerezo, Eduardo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [7] Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma
    Geynisman, Daniel M.
    John, William S.
    Miller, Taavy A.
    Asgarisabet, Parisa
    Guttenplan, Sarah B.
    Yin, Xin
    Savill, Kristin M. Zimmerman
    Mcallister, Lindsay
    Rosenblatt, Lisa
    ONCOLOGIST, 2024,
  • [8] Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
    Blesl, A.
    Binder, L.
    Hogenauer, C.
    Wenzl, H.
    Borenich, A.
    Pregartner, G.
    Berghold, A.
    Mestel, S.
    Kump, P.
    Baumann-Durchschein, F.
    Petritsch, W.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S427 - S428
  • [9] Real-World Outcomes of Dual Advanced Therapy in Inflammatory Bowel Disease
    Kellar, Amelia
    Dolinger, Michael
    Spencer, Elizabeth
    Dubinsky, Marla C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S4 - S4
  • [10] The Impact of Obesity on the Persistence of Advanced Therapies in Inflammatory Bowel Disease
    Hsu, W. C.
    Lin, S. H.
    Chiu, H. Y.
    Kuo, C. J.
    Chen, C. M.
    Su, M. Y.
    Wu, R. C.
    Chiu, C. T.
    Chang, C. W.
    Huang, T. Y.
    Pan, Y. B.
    Le, P. H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I673 - I675
12345